Six-Month Clinical Status as a Predictor of 24-Month Clinical Outcome in First-Admission Patients with Schizophrenia

References

• Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789–796
   PubMed Web of Science ®Google Scholar
• Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151 (6 suppl.):825–835
   Google Scholar
• Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane JM: Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994; 151:1774–1752
   Google Scholar
• Carpenter WT Jr, Conley RR, Buchanan RW, Breier A, Tam-minga CA: Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry 1995; 152:827–832
   Google Scholar
• Ereshefsky L: Treatment strategies for schizophrenia. Psychi-atr Ann 1995; 25:285–296
   Google Scholar
• Wasylenki DA: Psychotherapy of schizophrenia revisited. Hosp Commun Psychiatry 1992; 43:123–127
   PubMedGoogle Scholar
• Burns BJ, Santos AB: Assertive community treatment: an update of randomized trials. Psychiatr Serv 1995; 46:669–675
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Cola P, Way L, Thompson PA, Bastani B, Davies MA, Snitz B: Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993; 150:1630–1638
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Ziegler DM, Peachey TJ, Goodwin FK: Cost-effectiveness of clozapine therapy for severe psychosis. Psychi-atr Serv 1998; 49:829–831
   PubMedGoogle Scholar
• Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D: A comparison of clozapine and haloperidol in hospitalized patients with refractory schizo-phrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia [see com-ments]. N Engl J Med 1997; 337:809–815
   Google Scholar
• Albright PS, Livingstone S. Keegan DL, Ingham M, Shrik-hande S, LeLorier J: Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy—a retrospective analysis using the Saskatchewan Health Linkable Databases. Clin Drug Invest 1996; 11:289–299
   Web of Science ®Google Scholar
• Tollefson GD, Beasley CM Jr, Tamura RN, Tran PV, Potvin JH: Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dysldnesia with olan-zapine or haloperidol. Am J Psychiatry. 197; 154:1248-1254
   Google Scholar
• Davies A, Langley PC, Keks NA, Catts SV, Lambert T, Schweitzer I: Risperidone versus haloperidol: II. cost-effec-tiveness. Clin Ther 1998; 20:196–213
   PubMed Web of Science ®Google Scholar
• Marder SR, Van Putten T: Who should receive clozapine? Arch Gen Psychiatry 1988 45:865–867
   PubMed Web of Science ®Google Scholar
• Hoge MA, Davidson L, Griffith EE, Sledge WH, Howenstine RA: Defining managed care in public sector psychiatry. Hosp Commun Psychiatry 1994; 45:1085–1089
   PubMedGoogle Scholar
• Garnick DW, Hendricks AM, Dulski JD, Thorpe KE, Horgan C: Characteristics of private-sector managed care for mental health and substance abuse treatment. Hosp Commun Psychi-atry 1994; 45:1201–1205
   PubMedGoogle Scholar
• Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Jr: Effects of clozapine on positive and negative symptoms in outpatients with schizo-phrenia. Am J Psychiatry 1994; 151:20–26
   PubMed Web of Science ®Google Scholar
• Bromet EJ, Jandorf L, Fennig S, Lavelle J, Kovasznay B, Ram R, Tanenberg-Karant M, Craig T: Premorbid and clinical predictors of short-term course in first-admission psychoticpatients: Preliminary results. Psychol Med 1996; 26:953–962
   PubMed Web of Science ®Google Scholar
• Spitzer RL, Williams J, Gibbon M, First MB: The Structured Clinical Interview for DSM-III-R (SCID) I: history, rationale and description. Arch Gen Psychiatry 1992; 49:624–629
   PubMed Web of Science ®Google Scholar
• Fennig S, Kovasznay B, Rich C, Ram R, Pato C, Miller A, Rubinstein J, Carlson G, Schwartz JE, Phelan J, Lavelle J, Craig T, Bromet E: Six-month stability of psychiatric diagnosis in first admission patients with psychosis. Am J Psychiatry 1994; 151:1200–1208
   PubMed Web of Science ®Google Scholar
• Andreasen NC, Arndt S, Alliger R, Miller D, Flaum M: Symp-toms of schizophrenia: methods, meanings, and mechanisms. Arch Gen Psychiatry 1995; 52:341–351
   PubMed Web of Science ®Google Scholar
• Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, Day R, Bertelsen A: Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med 1992(monograph suppl 1992); 20: 1–97
   Google Scholar
• Woerner MG, Mannuzza S, Kane JM: Anchoring the BPRS: an aid to improved reliability. Psychopharm Bull 1988; 24:112–117
   PubMed Web of Science ®Google Scholar
• Heinrichs DW, Hanlon TE, Carpenter WT Jr: The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10:388–398
   PubMed Web of Science ®Google Scholar
• Marengo J, Harrow M, Sands J, Galloway C: European versus United States data on the course of schizophrenia. Am J Psychiatry 1991; 148:606–611
   Google Scholar
• Hegarty JD, Baldessarini RI, Tohen M, Waternaux C, Oepen G: One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994; 151:1409–1416
   PubMed Web of Science ®Google Scholar
• Ram R. Bromet EJ, Eaton WW, Pato C, Schwartz JE: The natural course of schizophrenia: a review of first-admission studies. Schizophr Bull 1992; 18:185–201
   Google Scholar
• Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharm 1993; 13:25–40
   PubMed Web of Science ®Google Scholar
• Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825–835
   PubMed Web of Science ®Google Scholar
• Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry. 1995; 166:712–26
   PubMed Web of Science ®Google Scholar
• Keefe RSE, Mohs RC, Losonczy MF, Davidson M, Silverman JM, Kendler KS, Horvath TB, Nora R, Davis KL: Characteris-tics of very poor outcome schizophrenia. Am J Psychiatry 1987; 144:889–895
   PubMed Web of Science ®Google Scholar
• Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiue CY, Cooper TB, Brodie JD: Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 1989; 146:905–908
   PubMed Web of Science ®Google Scholar
• Peralta V, de Leon J, Cuesta MJ: Are there more than two syndromes in schizophrenia? a critique of the positive-negative dichotomy. Br J Psychiatry 1992; 161:335–343
   PubMed Web of Science ®Google Scholar
• Yates WR, Jacoby CG, Andreasen NC: Cerebellar atrophy in schizophrenia and affective disorder. Am J Psychiatry 1987; 144:465–467
   PubMedGoogle Scholar
• Smith JV, Birchwood MJ: Specific and non-specific effects of educational intervention with families living with a schizo-phrenic relative. Br J Psychiatry 1987: 150:645–652
   PubMed Web of Science ®Google Scholar
• Liddle PF: Schizophrenic syndromes, cognitive performance and neurological dysfunction. Psycho, Med 1987; 17:49–57
   PubMed Web of Science ®Google Scholar
• Breier A, Schreiber JL, Dyer J, Pickar D: The National Insti-tute of Mental Health longitudinal study of chronic schizo-phrenia. Arch Gen Psychiatry 1991; 48:239–246
   PubMed Web of Science ®Google Scholar
• Harrow M, Grinker RR, Silverstein ML, Holzman P: Is mod-ern-day schizophrenia outcome still negative? Am J Psychia-try 1978; 135:1156–1162
   PubMed Web of Science ®Google Scholar
• Lieberman J, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, Woerner M, Borenstein M: Time course and biologic corre-lates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 1993; 50:369–376
   PubMed Web of Science ®Google Scholar
• Schooler NR: Translating treatment research findings into clinical action [editorial]. Am J Psychiatry 1994; 151:1719–1721
   Google Scholar
• Harding CM, Zubin J, Strauss JS: Chronicity in schizophrenia: fact, partial fact, or artifact? Hosp Commun Psychiatry 1987; 38:477–486
   PubMedGoogle Scholar